Kits and composition comprising: (i) a thermo-responsive hydrogel characterized by a viscosity suitable for hardening after administration on a subject's skin; (ii) a bacterial growth medium; and optionally, (iii) a population of non-pathogenic viable bacteria, are provided. Methods for topically delivering a therapeutic or cosmeceutical agent such as for inhibiting or reducing growth of microorganisms on a subject's skin are further provided.

Antimicrobial or non-antimicrobial compositions, sanitizing compositions and other compositions combining use of a propoxylated EO/PO block copolymer surfactant and/or propoxylated polymer in combination with at least one additional anionic and/or nonionic surfactant to provide concentrated compositions having a desired viscoelasticity at an active level of at least 18% are disclosed. Non-antimicrobial applications combining use of a propoxylated surfactant and/or propoxylated polymer in combination with at least one additional anionic and/or nonionic surfactant to provide compositions having a desired viscoelasticity are also disclosed. Methods of using concentrated and use compositions having desired foaming enhancement and stabilization are also disclosed.

Antimicrobial or non-antimicrobial compositions, sanitizing compositions and other compositions combining use of a propoxylated EO/PO block copolymer surfactant and/or propoxylated polymer in combination with at least one additional anionic and/or nonionic surfactant to provide concentrated compositions having a desired viscoelasticity at an active level of at least 18% are disclosed. Non-antimicrobial applications combining use of a propoxylated surfactant and/or propoxylated polymer in combination with at least one additional anionic and/or nonionic surfactant to provide compositions having a desired viscoelasticity are also disclosed. Methods of using concentrated and use compositions having desired foaming enhancement and stabilization are also disclosed.

The present invention discloses either or both in situ and a priori generated hydrogel wound dressings comprise one or more RTR components in low viscosity aqueous solution and one or more non-RTR components. A dressing, comprising at least one first RTR and an active component (AC) integrated within the RTR is also disclosed. The invention further discloses a method of treating a medical or cosmetic indication by a wound dressing, comprising either or both in situ and a priori generating hydrogel wound dressings by providing one or more RTR components in low viscosity aqueous solution and one or more non-RTR components. it and methods for treating a medical or cosmetic indication by providing a dressing with at least one first RTR and with at least one active component (AC) integrated within the RTR are also disclosed.

Disclosed herein are oral care compositions comprising at least one phosphate/acrylate copolymer, at least one cationic antibacterial agent, at least one synthetic anionic linear polycarboxylate polymer, at least one surfactant, and zinc lactate. Also disclosed herein are methods for the treatment and/or inhibition of gum disease or halitosis comprising contacting the oral cavity with the oral care compositions disclosed herein, as well as methods of making the oral care compositions disclose herein.

Disclosed herein are oral care compositions comprising at least one phosphate/acrylate copolymer, at least one cationic antibacterial agent, at least one synthetic anionic linear polycarboxylate polymer, at least one surfactant, and zinc lactate. Also disclosed herein are methods for the treatment and/or inhibition of gum disease or halitosis comprising contacting the oral cavity with the oral care compositions disclosed herein, as well as methods of making the oral care compositions disclose herein.

Hypotonic formulations of hydrogel forming polymers, preferably poloxamers, have been developed for enhanced delivery through mucosa of therapeutic, diagnostic, prophylactic or other agents, to epithelial tissues, especially those having a mucosal coating. The polymers are administered at a concentration above, at or less than their critical gelling concentration (CGC) under isotonic conditions. The hypotonicity of the formulation is adjusted so that the polymer gels at the lower concentration. A Poloxamer gel administered into the vagina or colorectum at its CGC will form a “plug” of gel in the lumen.

Hypotonic formulations of hydrogel forming polymers, preferably poloxamers, have been developed for enhanced delivery through mucosa of therapeutic, diagnostic, prophylactic or other agents, to epithelial tissues, especially those having a mucosal coating. The polymers are administered at a concentration above, at or less than their critical gelling concentration (CGC) under isotonic conditions. The hypotonicity of the formulation is adjusted so that the polymer gels at the lower concentration. A Poloxamer gel administered into the vagina or colorectum at its CGC will form a “plug” of gel in the lumen.

The present disclosure relates to a biodegradable polymer dispersion containing a lactic acid-based polymer, a lactic acid-based polymer and polyethylene glycol-containing block copolymer (PEG-PLA), and a hyaluronic acid mixture, wherein the biodegradable polymer dispersion has excellent physiological activity by itself, has excellent dispersion stability of the lactic acid-based polymer, and is capable of effectively supporting active ingredients. In addition, the present disclosure relates to a composition containing the biodegradable polymer dispersion and a skin improvement system.

An oral care composition, including a catalyzing enzyme and an anhydrous matrix configured to at least partially stabilize the catalyzing enzyme, wherein the anhydrous matrix includes a source of hydrogen peroxide, an acyl donor, a non-aqueous anhydrous liquid, and a surfactant mixture including sodium lauryl sulfate (SLS), Betaine, and a poloxamer.